drugset / Trial / NCT01472796
Vitamin D Augmentation of Tekturna (Aliskiren) in Hypertension
RandomizedParallel-groupTriple-blindTreatment
Summary
In this research study, the goal is to find out if a currently FDA-approved medication called Tekturna(Aliskiren) along with the addition of Vitamin D will lower blood pressure and improve heart function in the African American population. High blood pressure occurs earlier in life in African Americans, is more severe, and is associated with greater organ damage in relation to uncontrolled hypertension. Having low levels of Vitamin D is also very common in the African American population. Research has shown that there may be a link between low Vitamin D levels and the ability of high blood pressure medications to be fully effective.
Timeline
- Start
- 2011-07
- Primary completion
- 2013-07
- Completion
- 2014-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aliskiren | Small molecule | 300 mg | — |